<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669549</url>
  </required_header>
  <id_info>
    <org_study_id>ATR-101-202</org_study_id>
    <nct_id>NCT03669549</nct_id>
  </id_info>
  <brief_title>Nevanimibe HCl for the Treatment of Classic CAH</brief_title>
  <official_title>A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millendo Therapeutics US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millendo Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, intra-subject dose-titration open-label study of nevanimibe
      hydrochloride (HCl) for the treatment of classic congenital adrenal hyperplasia (CAH).
      Following a Screening Period of approximately 2-14 weeks, eligible subjects will enter a
      Baseline Period of approximately 2-8 weeks and then a 16-week Treatment Period. It is
      anticipated that the overall duration of the study per subject will range from 24-42 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Following an interim data review, further investment in nevanimibe has been discontinued
  </why_stopped>
  <start_date type="Actual">July 11, 2018</start_date>
  <completion_date type="Actual">July 12, 2020</completion_date>
  <primary_completion_date type="Actual">June 3, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving serum 17-OHP targets</measure>
    <time_frame>Through Day 113</time_frame>
    <description>&lt;= 2x ULN</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Congenital Adrenal Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Nevanimibe hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending dose level of oral nevanimibe hydrochloride beginning with 500 mg BID up to 2000 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevanimibe hydrochloride</intervention_name>
    <description>During the 16-week treatment period, all subjects will begin dosing with nevanimibe HCl 500 mg BID and be dose titrated to 1000 mg BID, 1500 mg BID, and 2000 mg BID as needed based on serum 17-OHP assessments every 4 weeks.</description>
    <arm_group_label>Nevanimibe hydrochloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented historical diagnosis of classic CAH due to 21-hydroxylase deficiency and/or
             historical documentation of elevated 17-OHP

          -  Chronic glucocorticoid replacement therapy for at least 6 consecutive months prior to
             screening

          -  Stable glucocorticoid and mineralocorticoid regimen for at least 4 weeks prior to
             screening and throughout the treatment period of the study

        Exclusion Criteria:

          -  Nonclassic CAH

          -  Other causes of adrenal insufficiency

          -  HIV, hepatitis B, or hepatitis C

          -  AST or ALT &gt;2x ULN, bilirubin or serum creatinine &gt;1.5x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Ribeirão Preto, Medicine Faculty (Faculdade de Medicina) of Ribeirão Preto</name>
      <address>
        <city>Ribeirão Preto</city>
        <zip>14051-140</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de São Paulo, Escola Paulista de Medicina</name>
      <address>
        <city>São Paulo</city>
        <zip>04037-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da FMUSP - Prédio do Instituto Central</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Endocrinology</name>
      <address>
        <city>Praha 1</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pitié-Salpetrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beilinson Hospital</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv-Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAH</keyword>
  <keyword>nevanimibe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

